• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

0
  • by alexperjescuadmin
  • in Oncology
  • — 11 Dec, 2007
Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
AudioMedica News
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
00:00 /
RSS Feed
Share
Link
Embed
Anton Hagenbeek
Anton Hagenbeek

ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.

Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071209_anton_hagenbeek.mp3]

Share

Tags: ashcommentslymphomamedicalmedicationpatientpodcastpodcastingreportreportsstudytoxicity

You may also like...

  • Abdenour Nabid Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer 24 Mar, 2013
  • ALK—Targeted Lung Cancer Drugs Benefited Real World Patients  ALK—Targeted Lung Cancer Drugs Benefited Real World Patients  7 Nov, 2018
  • Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival 28 Jul, 2009
  • Chronic Myeloid Leukemia 'To Become A Very Indolent Disease': Pregnancy Possible, Transplants Avoided—Mission Accomplished? Chronic Myeloid Leukemia ‘To Become A Very Indolent Disease’: Pregnancy Possible, Transplants Avoided—Mission Accomplished? 21 Apr, 2009

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Live Report from ASH:
    Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?
  • Next story Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • New Front Line Standard for Older Patients with…
    • Microbiome Diversity Key To Survival After…
    • Genomically Targeted Therapy Delays Advanced Breast…
    • Genomic-led AML Clinical Decision Making Within Seven Days
  • Home
  • Oncology
  • Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.